

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.SciCrunch.org) on May 3, 2025

Phospho-LAT (Tyr191) Antibody

RRID:AB_2157728

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 3584, RRID:AB_2157728)

Antibody Information

URL: http://antibodyregistry.org/AB_2157728

Proper Citation: (Cell Signaling Technology Cat# 3584, RRID:AB_2157728)

Target Antigen: Phospho-LAT (Tyr191)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10080104, AB_10828351, AB_2157728.

Antibody Name: Phospho-LAT (Tyr191) Antibody

Description: This polyclonal targets Phospho-LAT (Tyr191)

Target Organism: h, human

Antibody ID: AB_2157728

Vendor: Cell Signaling Technology

Catalog Number: 3584

Record Creation Time: 20241017T004844+0000

Record Last Update: 20241017T024347+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-LAT (Tyr191) Antibody.

No alerts have been found for Phospho-LAT (Tyr191) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Cong J, et al. (2024) Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions. *Immunity*.

Jenkins BJ, et al. (2023) Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. *Cell metabolism*, 35(7), 1132.

Cheng J, et al. (2023) Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. *Cell metabolism*, 35(6), 961.

Xu K, et al. (2021) Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. *Immunity*, 54(5), 976.

Dine E, et al. (2021) Positive feedback between the T cell kinase Zap70 and its substrate LAT acts as a clustering-dependent signaling switch. *Cell reports*, 35(12), 109280.

Sun C, et al. (2020) THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. *Cancer cell*, 37(2), 216.

Weulersse M, et al. (2020) Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. *Immunity*, 53(4), 824.

Li W, et al. (2020) Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. *Immunity*, 53(2), 456.

Clark DJ, et al. (2019) Transient protein accumulation at the center of the T cell antigen-presenting cell interface drives efficient IL-2 secretion. *eLife*, 8.

Lu Y, et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. *Cancer cell*, 33(6), 1048.

Courtney AH, et al. (2017) A Phosphosite within the SH2 Domain of Lck Regulates Its Activation by CD45. *Molecular cell*, 67(3), 498.